Kras inhibitors are a class of targeted cancer drugs designed to inhibit the kirsten rat sarcoma viral oncogene homolog (KRAS) protein, which is dysregulated in many cancers. KRAS mutations are commonly found in several types of cancer such as lung cancer, colorectal cancer and pancreatic cancer. Kras inhibitors work by blocking signals that help cancer cells grow uncontrollably. Some key advantages of KRAS inhibitors include increased survival rate, decreased tumor size, reduced cancer cell growth, and less side effects compared to chemotherapy. Growing burden of cancer worldwide and need for targeted therapies with better efficacy have fueled the demand for KRAS inhibitors in recent years.
The Global Kras Inhibitors Market is estimated to be valued at USD 104.5 Mn in 2024 and is expected to reach USD 146.6 Mn by 2031, growing at a compound annual growth rate (CAGR) of 4.98% from 2024 to 2031.
Key Takeaways
Key players operating in the Global Kras Inhibitors are Amgen, Mirati Therapeutics, Merck & Co, GlaxoSmithKline plc. Mirati Therapeutics' adagrasib is the first KRASG12C inhibitor to gain FDA approval for lung cancer treatment in 2022.
The rising incidence and prevalence of various cancers globally is a major factor driving the growth of the Global Kras Inhibitors Market. According to WHO, cancer burden is expected to rise by 50% globally by 2040. KRAS mutations are present in nearly one-fourth of all human cancers, providing a large target patient population for KRAS inhibitors.
Scientific advances in understanding KRAS biology and development of novel targeted therapies such as KRAS inhibitors are driving technological growth in cancer treatment. Several KRAS inhibitor products targeting different KRAS mutations are in clinical trials, which once approved will provide treatment options for various cancers.
Market Trends
Combination therapy is emerging as a key trend with KRAS inhibitors being studied along with other targeted therapies and immunotherapies to enhance treatment efficacy. Combining KRAS inhibitors with other cancer drugs that impact related pathways shows promise of achieving better clinical outcomes.
Personalized medicine is another trend, with development of KRAS inhibitor therapies specifically targeting different KRAS mutations prevalent in specific cancer types. This allows for more precise targeting of individual patient mutations, increasing response rates.
Market Opportunities
Approval and commercialization of late-stage KRAS inhibitor pipeline drugs over the forecast period offers significant revenue potential. Successful clinical data readout of combination therapies involving KRAS inhibitors will also open new opportunities.
Geographic expansion into emerging markets characterized by rising cancer burden presents lucrative opportunities for KRAS inhibitor manufacturers given the large target population base.
Impact of COVID-19 on Global Kras Inhibitors market
The COVID-19 pandemic has impacted the growth of the Global Kras Inhibitors market. During pre-COVID times, the market was growing at a steady pace due to the rise in cancer cases globally and increasing R&D efforts in developing targeted therapies for difficult-to-treat cancers. However, the outbreak of COVID-19 pandemic led to lockdowns across countries causing disruptions in clinical trials, manufacturing, and supply chain management of drug development companies. This resulted in delays in the development of new Kras inhibitors in the pipeline.
As countries relax lockdowns in a phased manner, companies are now adapting to the new normal by adhering to safety guidelines. They are leveraging digital technologies to advance virtual clinical trials and streamline supply chain operations. Companies are also prioritizing the development of drugs treating diseases with high unmet need like cancer. Regulatory agencies are providing conditional approvals and flexibility in clinical trials to expedite the launch of important new drugs. In the coming years, demand is expected to rise significantly as more effective targeted therapies receive approvals. Companies need to collaborate with healthcare providers, patient advocacy groups, and governments to improve access to new treatment options as the economic fallout of the pandemic may reduce affordability for some patients.
Geographical regions with high market value
North America accounts for the largest share of the global Kras inhibitors market in terms of value due to established healthcare infrastructure, high adoption of premium-priced targeted cancer therapies, and presence of major market players. The US market contributes significantly to the North American market value. Europe is the second largest region driven by large cancer patient population and favorable reimbursement system for new drugs in major countries like Germany, France, and the UK.
Fastest growing region
Asia Pacific region is expected to grow at the fastest rate during the forecast period owing to rising healthcare spending, growing cases of cancer due to changing lifestyle habits, increasing awareness about targeted therapies, and improving access through government initiatives. China and India are expected to drive the market growth in Asia Pacific as they are investing heavily in advancing their healthcare facilities to meet domestic needs of their huge population as well as to emerge as medical tourism destinations.
Get More Insights On- Global Kras Inhibitors Market
Get This Report in Japanese Language: 世界のKras阻害剤市場
Get This Report in Korean Language: 글로벌 크라스 억제제 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
(https://www.linkedin.com/in/ravina-pandya-1a3984191)